By: IPP Bureau
Last updated : September 14, 2026 9:48 am
The inspection was conducted over five days at the API manufacturing unit located in the Industrial Development Area, Pydibhimavaram, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh
Apitoria Pharma, the wholly owned subsidiary of Aurobindo Pharma, has successfully completed a US Food and Drug Administration (US FDA) inspection at its Unit-IV facility with zero observations, according to a regulatory filing made to the stock exchanges.
The inspection was conducted at the API manufacturing unit located in the Industrial Development Area, Pydibhimavaram, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh, and ran over five days, from September 7 to September 11, 2026.
A clean inspection outcome with zero observations is widely regarded as a strong endorsement of a facility's manufacturing practices and quality systems, and is typically viewed positively by investors as it signals continued, unhindered access to the US market for the site's products.
In its disclosure filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aurobindo Pharma reaffirmed its commitment to maintaining rigorous quality and compliance standards across all its manufacturing facilities.
The company added that it would keep the stock exchanges informed of any further developments related to the matter, in line with applicable regulatory norms.
The successful inspection adds to Aurobindo Pharma's track record of regulatory compliance across its manufacturing network, reinforcing confidence among stakeholders in the company's API and formulations business.